Share on StockTwits

Sabra Health Care REIT (NASDAQ:SBRA)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Group in a research report issued on Wednesday. They currently have a $32.00 price objective on the stock, down from their previous price objective of $34.00. Jefferies Group’s price objective would suggest a potential upside of 16.11% from the stock’s previous close.

Shares of Sabra Health Care REIT (NASDAQ:SBRA) opened at 27.56 on Wednesday. Sabra Health Care REIT has a 1-year low of $21.55 and a 1-year high of $31.17. The stock has a 50-day moving average of $28.24 and a 200-day moving average of $28.41. The company has a market cap of $1.303 billion and a P/E ratio of 49.35.

Sabra Health Care REIT (NASDAQ:SBRA) last announced its earnings results on Wednesday, July 30th. The company reported $0.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.55 by $0.02. The company had revenue of $42.97 million for the quarter, compared to the consensus estimate of $37.46 million. Sabra Health Care REIT’s revenue was up 33.1% compared to the same quarter last year. On average, analysts predict that Sabra Health Care REIT will post $2.15 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Friday, August 29th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 5.52%. The ex-dividend date is Wednesday, August 13th.

A number of other firms have also recently commented on SBRA. Analysts at MLV & Co
initiated coverage on shares of Sabra Health Care REIT in a research note on Friday, June 27th. They set a “buy” rating and a $31.00 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Sabra Health Care REIT in a research note on Tuesday, June 10th. They now have a $28.00 price target on the stock, up previously from $25.00. Finally, analysts at Barclays initiated coverage on shares of Sabra Health Care REIT in a research note on Friday, June 6th. They set an “equal weight” rating and a $31.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $31.00.

Sabra Health Care REIT, Inc, a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (NASDAQ:SBRA) that, through its subsidiaries, owns and invests in real estate serving the healthcare industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.